Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;48(5):1416-1419.
doi: 10.1161/STROKEAHA.116.016281. Epub 2017 Apr 6.

Using Artificial Intelligence to Reduce the Risk of Nonadherence in Patients on Anticoagulation Therapy

Daniel L Labovitz  1 , Laura Shafner  2 , Morayma Reyes Gil  1 , Deepti Virmani  1 , Adam Hanina  1
Affiliations

Using Artificial Intelligence to Reduce the Risk of Nonadherence in Patients on Anticoagulation Therapy

Daniel L Labovitz et al. Stroke. 2017 May.

Abstract

Background and purpose: This study evaluated the use of an artificial intelligence platform on mobile devices in measuring and increasing medication adherence in stroke patients on anticoagulation therapy. The introduction of direct oral anticoagulants, while reducing the need for monitoring, have also placed pressure on patients to self-manage. Suboptimal adherence goes undetected as routine laboratory tests are not reliable indicators of adherence, placing patients at increased risk of stroke and bleeding.

Methods: A randomized, parallel-group, 12-week study was conducted in adults (n=28) with recently diagnosed ischemic stroke receiving any anticoagulation. Patients were randomized to daily monitoring by the artificial intelligence platform (intervention) or to no daily monitoring (control). The artificial intelligence application visually identified the patient, the medication, and the confirmed ingestion. Adherence was measured by pill counts and plasma sampling in both groups.

Results: For all patients (n=28), mean (SD) age was 57 years (13.2 years) and 53.6% were women. Mean (SD) cumulative adherence based on the artificial intelligence platform was 90.5% (7.5%). Plasma drug concentration levels indicated that adherence was 100% (15 of 15) and 50% (6 of 12) in the intervention and control groups, respectively.

Conclusions: Patients, some with little experience using a smartphone, successfully used the technology and demonstrated a 50% improvement in adherence based on plasma drug concentration levels. For patients receiving direct oral anticoagulants, absolute improvement increased to 67%. Real-time monitoring has the potential to increase adherence and change behavior, particularly in patients on direct oral anticoagulant therapy.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02599259.

Keywords: anticoagulants; artificial intelligence; patient compliance; patient outcome assessment; stroke.

PubMed Disclaimer

Conflict of interest statement

Conflict(s)-of-Interest/Disclosure(s)

Daniel L. Labovitz, Deepti Virmani, and Morayma Reyes Gil are employees of Montefiore Medical Center, Bronx, NY. Laura Shafner and Adam Hanina are employees of AiCure, New York, NY, USA.

Figures

Figure 1
Figure 1
Mean Cumulative Adherence Per Patient Based on AI Platform (Intervention Group)
Figure 2
Figure 2
Mean Percentage of Samples Marked as Adherent Over Time (Above Cmin)
See this image and copyright information in PMC

References

    1. Bauer KA. Pros and Cons of New Oral Anticoagulants. Hematology Am Soc Hematol Educ Program. 2013;2013:464–470. - PubMed
    1. Ten Cate H. New Oral Anticoagulants: Discussion on Monitoring and Adherence Should Start Now! Thromb J. 2013;11:8. - PMC - PubMed
    1. Favaloro EJ, Lippi G. The New Oral Anticoagulants and the Future of Haemostasis Laboratory Testing. Biochem Med (Zagreb) 2012;22:329–341. - PMC - PubMed
    1. Yao X, Abraham NS, Alexander GC, Crown W, Montori VM, Sangaralingham LR, et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2016;5:e003074. - PMC - PubMed
    1. Song X, Sander SD, Varker H, Amin A. Patterns and Predictors of Use of Warfarin and Other Common Long-term Medications in Patients with Atrial Fibrillation. Am J Cardiovasc Drugs. 2012;12:245–253. - PubMed

Publication types

Associated data